IceCure reports ICESECRET ProSense kidney cancer trial; recurrence-free rate rises to 89.4% for tumors ≤3 cm

Reuters

Mar 25

IceCure reports ICESECRET ProSense kidney cancer trial; recurrence-free rate rises to 89.4% for tumors ≤3 cm

IceCure Medical announced positive top-line 5-year results from its ICESECRET clinical trial of ProSense for the treatment of small renal masses in kidney cancer patients.
At a median follow-up of four years, the recurrence-free rate reached 83.9% in 112 evaluated patients and rose to 89.4% in a subgroup with tumors ≤3 cm, no prior kidney cancer, and successful initial procedures.
Within the evaluated group, 12 patients underwent a second cryoablation procedure at a mean of 1.73±1.2 years.
More detailed data will be presented by Principal Investigator Prof. Halahmi Sarel at the European Conference on Interventional Oncology 2026 in Basel.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IceCure Medical Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN18929) on March 25, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2622075113"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2622075113\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2622075113?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-25 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622075113","market":"us","top_or_hot":-1,"title":"IceCure reports ICESECRET ProSense kidney cancer trial; recurrence-free rate rises to 89.4% for tumors ≤3 cm","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      IceCure reports ICESECRET ProSense kidney cancer trial; recurrence-free rate rises to 89.4% for tumors ≤3 cm\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          IceCure Medical announced positive top-line 5-year results from its ICESECRET clinical trial of ProSense for the treatment of small renal masses in kidney cancer patients.\n        </li>\n<li>\n          At a median follow-up of four years, the recurrence-free rate reached 83.9% in 112 evaluated patients and rose to 89.4% in a subgroup with tumors ≤3 cm, no prior kidney cancer, and successful initial procedures.\n        </li>\n<li>\n          Within the evaluated group, 12 patients underwent a second cryoablation procedure at a mean of 1.73±1.2 years.\n        </li>\n<li>\n          More detailed data will be presented by Principal Investigator Prof. Halahmi Sarel at the European Conference on Interventional Oncology 2026 in Basel.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/ICCM\">IceCure Medical Ltd.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: LN18929) on March 25, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IceCure reports ICESECRET ProSense kidney cancer trial; recurrence-free rate rises to 89.4% for tumors ≤3 cm</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIceCure reports ICESECRET ProSense kidney cancer trial; recurrence-free rate rises to 89.4% for tumors ≤3 cm\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-25 20:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      IceCure reports ICESECRET ProSense kidney cancer trial; recurrence-free rate rises to 89.4% for tumors ≤3 cm\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          IceCure Medical announced positive top-line 5-year results from its ICESECRET clinical trial of ProSense for the treatment of small renal masses in kidney cancer patients.\n        </li>\n<li>\n          At a median follow-up of four years, the recurrence-free rate reached 83.9% in 112 evaluated patients and rose to 89.4% in a subgroup with tumors ≤3 cm, no prior kidney cancer, and successful initial procedures.\n        </li>\n<li>\n          Within the evaluated group, 12 patients underwent a second cryoablation procedure at a mean of 1.73±1.2 years.\n        </li>\n<li>\n          More detailed data will be presented by Principal Investigator Prof. Halahmi Sarel at the European Conference on Interventional Oncology 2026 in Basel.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/ICCM\">IceCure Medical Ltd.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: LN18929) on March 25, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ICCM","symbol_name":"IceCure Medical Ltd.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL7P6bb1:1","article_id":"2622075113","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622075113","pubTimestamp":1774441859,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"IceCure Medical announced positive top-line 5-year results from its ICESECRET clinical trial of ProSense for the treatment of small renal masses in kidney cancer patients.At a median follow-up of four years, the recurrence-free rate reached 83.9% in 112 evaluated patients and rose to 89.4% in a subgroup with tumors ≤3 cm, no prior kidney cancer, and successful initial procedures.Within the evaluated group, 12 patients underwent a second cryoablation procedure at a mean of 1.73±1.2 years.More detailed data will be presented by Principal Investigator Prof. Halahmi Sarel at the European Conference on Interventional Oncology 2026 in Basel.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IceCure Medical Ltd. published the original content us","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ICCM":"IceCure Medical Ltd.","BK4082":"医疗保健设备"},"translate_title":"IceCure报告ICESECRET ProSense肾癌试验；肿瘤≤3 cm无复发率升至89.4%","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ICCM":0.9},"content_text":"IceCure reports ICESECRET ProSense kidney cancer trial; recurrence-free rate rises to 89.4% for tumors ≤3 cm\n    \n\n\n          IceCure Medical announced positive top-line 5-year results from its ICESECRET clinical trial of ProSense for the treatment of small renal masses in kidney cancer patients.\n        \n\n          At a median follow-up of four years, the recurrence-free rate reached 83.9% in 112 evaluated patients and rose to 89.4% in a subgroup with tumors ≤3 cm, no prior kidney cancer, and successful initial procedures.\n        \n\n          Within the evaluated group, 12 patients underwent a second cryoablation procedure at a mean of 1.73±1.2 years.\n        \n\n          More detailed data will be presented by Principal Investigator Prof. Halahmi Sarel at the European Conference on Interventional Oncology 2026 in Basel.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IceCure Medical Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN18929) on March 25, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}